Drugs / Glycyrrhetinic Acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00384384 | Aug 2006 → Apr 2007 | end stage renal failure | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03998982 Comparator | Jun 2019 → Jun 2021 | autoimmune thrombocytopenia | Shandong University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glycyrrhetinic Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03998982 ↗ |
| Known as | 18B Glycyrrhetinic acid | “Background: 18B Glycyrrhetinic acid (active compound of Licorice)” NCT00384384 ↗ |
| Action | Inhibit | “18B Glycyrrhetinic acid is an inhibitor of 11B Hydroxysteroid dehydrogenase type 1” NCT00384384 ↗ |
| Route | Oral | “comparing oral 18b Glycyrrhetinic acid with placebo” NCT00384384 ↗ |
| Target | HSD11B1 | “18B Glycyrrhetinic acid is an inhibitor of 11B Hydroxysteroid dehydrogenase type 1” NCT00384384 ↗ |